Invesco Ltd. Acquires 24,731 Shares of Cardlytics, Inc. $CDLX

Invesco Ltd. raised its position in Cardlytics, Inc. (NASDAQ:CDLX) by 34.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,054 shares of the company’s stock after buying an additional 24,731 shares during the period. Invesco Ltd. owned 0.19% of Cardlytics worth $177,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. ProShare Advisors LLC acquired a new position in Cardlytics in the fourth quarter valued at approximately $43,000. Wells Fargo & Company MN grew its position in Cardlytics by 46.0% in the fourth quarter. Wells Fargo & Company MN now owns 21,106 shares of the company’s stock valued at $78,000 after purchasing an additional 6,649 shares in the last quarter. Two Sigma Advisers LP grew its position in Cardlytics by 44.1% in the fourth quarter. Two Sigma Advisers LP now owns 36,900 shares of the company’s stock valued at $137,000 after purchasing an additional 11,300 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Cardlytics by 112.2% in the 4th quarter. BNP Paribas Financial Markets now owns 41,907 shares of the company’s stock valued at $155,000 after acquiring an additional 22,162 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Cardlytics by 123.8% in the 1st quarter. Deutsche Bank AG now owns 48,728 shares of the company’s stock valued at $89,000 after acquiring an additional 26,958 shares during the period. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Evercore ISI cut their target price on shares of Cardlytics from $3.00 to $2.00 and set an “in-line” rating for the company in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $2.25.

Cardlytics Price Performance

CDLX stock opened at $0.91 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 2.87. Cardlytics, Inc. has a 12 month low of $0.85 and a 12 month high of $5.25. The firm has a market cap of $48.47 million, a P/E ratio of -0.25 and a beta of 1.19. The company’s 50-day moving average price is $1.57 and its two-hundred day moving average price is $1.77.

Insider Activity

In related news, CEO Amit Gupta sold 68,685 shares of Cardlytics stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $1.12, for a total transaction of $76,927.20. Following the sale, the chief executive officer directly owned 491,759 shares of the company’s stock, valued at approximately $550,770.08. The trade was a 12.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 156,265 shares of company stock worth $187,768. Insiders own 4.40% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.